Effectiveness of polyene phosphatidylcholine and its combination with other drugs in patients with liver diseases based on real-world research

References

• Mu X, Yin R, Wang D, et al. Hepatic toxicity following actinomycin D chemotherapy in treatment of familial gestational trophoblastic neoplasia: a case report[J]. Medicine (Baltimore). 2018;97(38):e12424.
   Google Scholar
• Wang J, Chen G . Dimethylacetamide-induced toxic hepatitis in spandex workers: clinical presentation and treatment outcomes[J]. QJM. 2020;113(5):324–329.
   Google Scholar
• Li M, Luo Q, Tao Y, et al. Pharmacotherapies for drug-induced liver injury: a current literature review. Front Pharmacol. 2022 Jan 5;12:806249.
   Google Scholar
• Xiang Z, P CY, F MK, et al. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review[J]. BMC Gastroenterol. 2013;13(1):140.
   Google Scholar
• Ting-Ting F, Xiao-Ying Y, Shan-Shan H, et al. TLR-2-mediated metabolic reprogramming participates in polyene phosphatidylcholine-mediated inhibition of M1 macrophage polarization[J]. Immunol Res. 2020;68(1):28–38.
   Google Scholar
• Pan W, T HW, W XH, et al. Polyene Phosphatidylcholine inhibited the inflammatory response in LPS-stimulated macrophages and ameliorated the adjuvant-induced rat arthritis[J]. Am J Transl Res. 2017;9(9):4206.
   Google Scholar
• Zhang QZ, Liu YL, Wang YR, et al. Effects of telmisartan on improving leptin resistance and inhibiting hepatic fibrosis in rats with non-alcoholic fatty liver disease. Exp Ther Med. 2017;14(3):2689–2694.
   Google Scholar
• Okiyama W, Tanaka N, Nakajima T, et al. Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress. J Hepatol. 2009;50:1236–1246.
   Google Scholar
• Lieber CS, Leo MA, Aleynik SI, et al. Polyenylphosphatidylcholine decreases alcohol-induced oxidative stress in the baboon. Alcohol Clin Exp Res. 1997;21:375–379.
   Google Scholar
• Cao M, Li X, Zhang B, et al. The effect of polyene phosphatidyl choline intervention on non-alcoholic steatohepatitis and related mechanism[J]. Am J Transl Res. 2016;8(5):2325.
   Google Scholar
• Committee of the treatment with polyenphosphatidylcholine in patients with liver diseases.Experts consensus on the treatment of polyenphosphatidylcholine in patients with liver diseases. 2017;29(6):331. Chin. J. Liver Dis.
   Google Scholar
• Lu Y, Feng T, Zhao J, et al. Polyene phosphatidylcholine ameliorates high fat diet-Induced non-alcoholic fatty liver disease via remodeling metabolism and inflammation. Front Physiol. 2022 Feb 28;13:810143.
   Google Scholar
• Lei X, Zhang J, Xu Q, et al. Exploring the efficacy and safety of polyene phosphatidylcholine for treatment of drug-induced liver injury using the Roussel Uclaf causality assessment method: a propensity score matching comparison. J Int Med Res. 2021 Aug;49(8):3000605211039810.
   Google Scholar
• Fan J-G, Ying L, Yu Z, et al. Effectiveness and economic evaluation of polyene phosphatidyl choline in patients with liver diseases based on real-world research front pharmacol. Front Pharmacol. 2022 Mar 7;13:806787.
   Google Scholar
• Kanaan S, Hettie G, Loder E, et al. Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia. 2020 Nov;40(13):1511–1522.
   Google Scholar
• Gou M, Si H, Zhang Y, et al. Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study. Sci Rep. 2018 Mar 15 8(1):4602.
   Google Scholar
• Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98(8):253–259.
   Google Scholar
• Li L, Zhang XJ, Lan Y, et al. Treatment of non-alcoholic fatty liver disease by Qianggan Capsule. Chin J Integr Med. 2010;16:23–27.
   Google Scholar
• Wang T, Chen DF. Effect of polyene phosphatidyl choline on hepatocyte steatosis via PPARα/CPT-1A pathway. Chin J Hepatol. 2016;24:291–296.
   Google Scholar
• He B, Wu L, Xie W, et al. The imbalance of Th17/Treg cells is involved in the progression of non-alcoholic fatty liver disease in mice[J]. BMC Immunol. 2017;18. 10.1186/s12865-017-0215-y.
   Google Scholar
• Zhang H, Jiang T, Yu H, et al. Polyene phosphatidylcholine protects against radiation induced tissue injury without affecting radiotherapeutic efficacy in lung cancer[J]. Am J Cancer Res. 2019;9(6):1091–1103.
   Google Scholar
• Yu H, Yu Z, Huang H, et al. Gut microbiota signatures and lipids metabolism profiles by exposure to polyene phosphatidylcholine[J]. BioFactors. 2019;45(3):439–449.
   Google Scholar
• Senior JR. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future. Clin Pharmacol Ther. 2012 Sep;92(3):332–339. Epub 2012 Aug 8.
   Google Scholar
• Sas E, Grinevich V, Efimov O, et al. Beneficial influence of polyunsaturated phosphatidylcholine enhances functional liver condition and liver structure in patients with nonalcoholic steatohepatitis. Results of prolonged randomized blinded prospective clinical study[J]. J Hepatol. 2013;58(6):S549.
   Google Scholar
• Sas E, Grinevich V, Kravchuk U, et al. Polyunsaturated phosphatidylcholine reduces insulin resistance and hepatic fibrosis in patients with alcoholic liver disease: results of randomized blinded prospective clinical study[J]. J Hepatol. 2011;54(11):S207.
   Google Scholar
• Yu-kun J, Yan L, Wei L. Clinical study on treatment of alcoholic fatty liver disease with yishanfu [J]. J Clin Hepatol. 2008;11(2):104–105.
   Google Scholar
• Shor D B-A, Bashi T, Lachnish J, et al. Phosphorylcholine-tuftsin compound prevents development of dextransulfate-sodium-salt induced murine colitis: implications for the treatment of human inflammatory bowel disease. J Autoimmun. 2015;56:111–117.
   Google Scholar
• Bashi T, Shovman O, Fridkin M, et al. Novel therapeutic compound tuftsin-phosphorylcholine attenuates collagen-induced arthritis. Clin Exp Immunol. 2016;184:19–28.
   Google Scholar
• Treede I, Braun A, Sparla R, et al. Anti-inflammatory effects of phosphatidylcholine. J Biol Chem. 2007 Sep 14;28237:27155–27164. Epub 2007 Jul 18.
   Google Scholar
• Lv H, Zhen C, Liu J, et al. Unraveling the potential role of glutathione in multiple forms of cell death in cancer therapy[J]. Oxid Med Cell Longev. 2019;2019;1–16.
   Google Scholar
• Locigno R, Castronovo V. Reduced glutathione system: role in cancer development, prevention and treatment (Review)[J]. Int.j.oncol. 2001;19(2):221–236.
   Google Scholar
• Na J, Lu L, Wang T, et al. Reduced glutathione attenuates liver injury induced by methyl parathion in rats.[J]. Toxicol Mech Methods. 2010;20(2):69–74.
   Google Scholar
• Jiang W, Xu S, Guo H, et al. Magnesium isoglycyrrhizinate prevents the nonalcoholic hepatic steatosis via regulating energy homeostasis[J]. J Cell Mol Med. 2020;24(13):7201–7213.
   Google Scholar
• Xie C, Li X, Wu J, et al. Anti-inflammatory activity of magnesium isoglycyrrhizinate through inhibition of phospholipase A2/Arachidonic acid pathway[J]. Inflammation. 2015;38(4):1639–1648.
   Google Scholar
• Ma X, Liu S, Zhang J, et al. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis. BMC Gastroenterol. 2020 Jan 14; 20(1):10.
   Google Scholar